$NNVC: Pioneering the Future of Antiviral Therapies NanoViricides, Inc., a clinical-stage biotechnology company, is transforming the landscape of antiviral medicine with its proprietary nanomedicine platform. At the forefront of its efforts is NV-387, an innovative broad-spectrum antiviral drug. NV-387 addresses a critical gap in the treatment of infectious diseases, targeting a range of viruses such as respiratory syncytial virus (RSV), influenza, COVID-19, and Mpox. As NanoViricides advances NV-387 through clinical trials, the drug has the potential to revolutionize how viral diseases are managed globally.
NV-387: A Cutting-Edge Antiviral Solution
NV-387 utilizes a unique “Re-Infection Blocker” mechanism, which sets it apart from conventional antiviral treatments. Instead of targeting specific viral proteins that are prone to mutation, NV-387 mimics human cellular structures to bind to and neutralize virus particles. This prevents the virus from infecting healthy cells, effectively halting the spread of infection within the body.
Preclinical trials have demonstrated NV-387’s impressive efficacy. In studies, the drug outperformed standard treatments like Tamiflu® and Xofluza® for influenza, while also curing lethal RSV infections in animal models. Notably, NV-387 offers broad-spectrum activity, which means it remains effective against various viral strains, including those with mutations
In Phase I clinical trials, NV-387 proved to be highly safe and well-tolerated. Conducted by NanoViricides’ partner, Karveer Meditech Pvt. Ltd., the trials reported no adverse effects, even at high doses. These findings underscore the drug’s potential as a game-changing antiviral therapy